Stage I Uterine Cancer
Patients diagnosed with Stage I uterine cancer have cancer that has not spread outside the uterus. Stage IA is cancer confined to the inner layer of cells of the uterus (endometrium). Stage IB is cancer that invades less than one half of the muscle wall of the uterus. Stage IC is cancer that invades more than one half of the muscle wall of the uterus.
A variety of factors ultimately influence a patient’s decision to receive treatment of cancer. The purpose of receiving cancer treatment may be to improve symptoms through local control of the cancer, increase a patient’s chance of cure, or prolong a patient’s survival. The potential benefits of receiving cancer treatment must be carefully balanced with the potential risks of receiving cancer treatment.
The following is a general overview of the treatment of Stage I uterine cancer. Circumstances unique to your situation and prognostic factors of your cancer may ultimately influence how these general treatment principles are applied. The information on this Web site is intended to help educate you about your treatment options and to facilitate a mutual or shared decision-making process with your treating cancer physician.
Most new treatments are developed in clinical trials. Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. The development of more effective cancer treatments requires that new and innovative therapies be evaluated with cancer patients. Participation in a clinical trial may offer access to better treatments and advance the existing knowledge about treatment of this cancer. Clinical trials are available for most stages of cancer. Patients who are interested in participating in a clinical trial should discuss the risks and benefits of clinical trials with their physician. To ensure that you are receiving the optimal treatment of your cancer, it is important to stay informed and follow the cancer news in order to learn about new treatments and the results of clinical trials.
Stage I uterine cancer is curable with surgery alone for the majority of patients. Optimal treatment may require additional therapeutic approaches in selected situations. Thus, it is important for patients to be treated at a medical center that can offer multi-modality treatment from gynecologic oncologists and radiation oncologists.
The standard treatment for Stage I uterine cancer is a total abdominal hysterectomy (removal of the uterus) and bilateral salpingo-oophorectomy (removal of the fallopian tubes and ovaries) with or without removal of the pelvic and para-aortic lymph nodes. Despite complete surgical resection of all cancer, 5-20% of patients will experience recurrence of their cancer. This is because some patients with Stage I cancer have microscopic cancer cells, called micrometastases, that have spread outside the uterus and therefore were not removed by surgery. These cancer cells cannot be detected with any of the currently available tests. The presence of these micrometastases causes relapses that follow treatment with surgery alone. Following surgery, some patients may benefit from additional treatment (adjuvant therapy) to decrease the risk of cancer recurrence. There is a progressive increase in local and distant cancer recurrences in patients with Stage IA, IB and IC disease and in patients with well, moderately and poorly differentiated cancers following treatment with surgery alone. To learn more about surgery, go to Surgery for Uterine Cancer.
Adjuvant therapy is the delivery of cancer treatment following local treatment with surgery and may include chemotherapy, radiation therapy and/or biologic therapy.
Radiation therapy is the most commonly used adjuvant therapy for early-stage uterine cancer. The decision about whether to use radiation therapy is often based on a woman’s risk of cancer recurrence. Women at low risk of recurrence may be treated with surgery alone, while women at higher risk of recurrence may be treated with surgery followed by radiation therapy. Risk of recurrence is influenced by characteristics such as the extent of the cancer and the grade of the cancer. The grade of the cancer refers to how abnormal the cancer cells appear; higher-grade cancers have a higher risk of recurrence.
Women who are candidates for adjuvant radiation therapy may be treated with external beam radiation therapy to the pelvis and/or vaginal brachytherapy.
Adjuvant External Beam Radiation Therapy: External beam radiation therapy (EBRT) is given via machines called linear accelerators, which produce high-energy external radiation beams that penetrate the tissues and deliver the radiation dose deep into the areas where the cancer resides. Studies suggest that adjuvant radiation therapy to the pelvis reduces the risk of cancer recurrence but does not improve overall survival for most women with early-stage uterine cancer. 
Adjuvant Brachytherapy: Brachytherapy treatment involves the placement of a radioactive isotope into the vagina in order to treat the “vaginal cuff” region. The vaginal cuff is the part of the vagina that was closest to the uterus; it is a common site of uterine cancer recurrence. Studies suggest that brachytherapy reduces the risk of cancer recurrence in the vagina with fewer side effects than external radiation therapy to the pelvis. Brachytherapy can, however, adversely affect sexual function. Furthermore, the effect on overall survival is likely to be small.
Strategies to Improve Treatment
The progress that has been made in the treatment of Stage I uterine cancer has resulted from the development of multi-modality treatments and doctor and patient participation in clinical trials. Future progress in the treatment of Stage I uterine cancer will result from continued participation in appropriate clinical trials. Currently, there are several areas of active exploration aimed at improving the treatment of uterine cancer.
Minimally invasive surgery: Traditionally, surgery for uterine cancer has been performed using a procedure known as a laparotomy. During a laparotomy, the surgeon makes a large incision in the abdomen in order to view and remove the uterus and other organs. A less invasive approach to surgery is laparoscopy, in which the surgeon makes only a few small incisions in the abdomen and views the inside of the abdomen using a small camera. Minimally invasive surgery may also be performed using robotics, in which a surgeon remotely operates a machine that holds the surgical instruments. Potential benefits of minimally invasive surgery include faster recovery time and less pain. Studies conducted thus far suggest that minimally invasive surgery is a safe and effective alternative to laparotomy for selected women with uterine cancer. Other studies are underway.
Adjuvant chemotherapy: Chemotherapy is commonly used in the treatment of advanced uterine cancer. The question of whether it also benefits women with high-risk early-stage cancer is being addressed in ongoing clinical trials.
Preservation of fertility: Up to 5% of uterine cancer diagnoses occur in women under the age of 40, many of whom have not yet had children. For some of these women, it may be possible to preserve the uterus and the ability to have children after cancer treatment by treating the cancer with a progestin (a hormonal therapy drug). This option is usually only considered for women with very early-stage and low-grade cancer.
Supportive Care: Supportive care refers to treatments designed to prevent and control the side effects of cancer and its treatment. Side effects not only cause patients discomfort, but also may prevent the optimal delivery of therapy at its planned dose and schedule. In order to achieve optimal outcomes from treatment and improve quality of life, it is imperative that side effects resulting from cancer and its treatment are appropriately managed. For more information, go to Managing Side Effects.
 Lu KH. Management of early-stage endometrial cancer. Seminars in Oncology. 2009;36:137-144.
 Humphrey MM, Apte SM. The use of minimally invasive surgery for endometrial cancer. Cancer Control. 2009;16:30-37.